Article
Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA.
Future oncology (London, England) - 1 Nov 2021
Tsuboi Masahiro, Weder Walter, Escriu Carles, Blakely Collin, He Jianxing, Dacic Sanja, Yatabe Yasushi, Zeng Lingmin, Walding Andrew, Chaft Jamie E
Abstract excerpt
Osimertinib is a third-generation, irreversible oral EGFR-tyrosine kinase inhibitor), that potently inhibits EGFR-tyrosine kinase inhibitor-sensitizing mutations and T790M resistance mutations together with efficacy in CNS metastases in patients with non-small-cell lung cancer (NSCLC). Here we describe the rationale and design for the Phase III NeoADAURA study (NCT04351555), which will evaluate neoadjuvant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.